Denali Therapeutics Inc. (DNLI) › Operating IncomeDenali Therapeutics Inc. (DNLI) — Operating IncomeAnnual figures by period end, from SEC filings.2016-12-31: -$87.43M2017-12-31: -$90.14M2018-12-31: -$46.37M2019-12-31: -$213.18M2020-12-31: $62.72M2021-12-31: -$295.75M2022-12-31: -$340.74M2023-12-31: -$196.70M2024-12-31: -$487.34M2025-12-31: -$555.34M-$555.34M2016-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31-$555.34M—2026-02-26From 2025-01-012024-12-31-$487.34M—2026-02-26From 2024-01-012023-12-31-$196.70M—2026-02-26From 2023-01-012022-12-31-$340.74M—2025-02-27From 2022-01-012021-12-31-$295.75M-571.6%2024-02-28From 2021-01-012020-12-31$62.72M—2023-02-27From 2020-01-012019-12-31-$213.18M—2022-02-28From 2019-01-012018-12-31-$46.37M—2021-02-26From 2018-01-012017-12-31-$90.14M—2020-02-27From 2017-01-012016-12-31-$87.43M—2019-03-12From 2016-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)